Structure of the Prescription Drug Market & Drug Prices

Stephen W. Schondelmeyer, PharmD, PhD, FAPhA


CMC Endowed Chair in Pharmaceutical Management & Economics Professor & Director, *PRIME* Institute Dept. of Pharmaceutical Care & Health Systems College of Pharmacy, University of Minnesota

June 20, 2024






Role of Pharmaceuticals in Health Care & Society & The Economy







The Nation's Health Dollar: 2023 (FY 2023, \$ 4.666 trillion) Where Did It Go?



PRIME Institute

University of Minnesota

What Role Did Drugs Play?

Are Drugs Used in Other Sectors?

YES! Other sectors that include Rx drugs.

All Settings includes:

- * Hospitals, hospices, other inpatient care
- * Physician dispensing
- * Clinics (specialty meds)
- * Military, VHA, Tricare
- * Federal Qualified Health Clinics, PHS, IHS
- * Patient Assistance Programs, samples
- * Other (prisons, schools, state facilities, etc.)

Rx Drugs in All Settings* ~19.4%





2023 U.S. Data

GDP per Person \$79,508

Median Salary per Person \$ 53,490

Personal Health Exp. per Person \$ 11,689


All Rx Drugs Exp. per Person \$ 2,714

Outpatient Rx Exp. per Person \$ 1,235



Sources of Payment for Health Care

Insurance Coverage Status of U.S. Population



Note: Persons may have insurance from more than one of the above sources so that percentages may total to more than 100.0%.

Source: Keehan SP, Fiore JA, Poisal JA, Cuckler GA, Sisko AM, Smith SD, Madison AJ, Rennie KE, National Health Expenditure Projections, 2022–31: Growth To Stabilize Once The COVID-19 Public Health Emergency Ends, Health Affairs, 42, No. 7 (2023): 886–898, 12 pp., at doi:10.1377/hlthaff.2023.00403



The Pharmaceutical Market

Drug Product Market

- (manufacturers, therapeutic classes, small molecules vs biologicals)
- (Rx vs OTC, brand vs generic vs specialty)
- Pharmacy Services
 - (dispensing, consultation, pharmaceutical care, shipping, other)
 - (drug administration, vaccine administration, med therapy management)
- Health Insurance & Benefits Market
 - (pharmacy benefit vs medical benefit)
 - (fee-for service, capitation or risk, benefit mgmt., salary)





Market Segments by Product Type

What are the major market segments for pharmaceuticals?

• **Brand Name** (NDA or BLA-approved, 1st NDA holder)

Single Source (SS)--Patented, Market Exclusivity Innovator Multiple Source (IMS)--Off-Patent Brand

- Generics (ANDA-approved, multiple source) Non-Innovator Multiple Source (NMS) Single Source Generics (SSG)
- Specialty Drugs (Biologics & High Cost Drugs) Prescription

Non-Prescription

Over-the-Counter (OTC) Drugs

Most New OTCs switched from Rx Status

• Vitamins, Minerals, Nutritional & Natural Products



Methods to Establish Price

What approaches can a pharmaceutical firm use to determine its price?

- Cost of Production
- Cost of Production + ROI
- Cost of Production + ROI + R&D Cost-Based Methods

Opportunity-Based Cost Methods

- Cost of Alternative Therapies (diet, surgery, exercise, group therapy, etc.)
- Cost of Alternative Drug Therapy (Other drug, dose form, strength, comb.)
- Cost of Not Treating the Condition
- Value of Life Extension or Quality-Adjusted Life Years (QALYs)
- Price of Other "Peer" Drug Therapies






Drug Pricing Trends

- Price at Introduction
- Price In Various Channels (discriminatory pricing)
- Price Changes Over Time (inflation)
- Price Relative to Other Products
 (generics & biosimilars / real price competition begins)
- **Payment Policy** (Payer policy & *payment limits*)
- Price Effect on Affordability & Access
 (coverage & subsidies vs uninsured & lack of health care)





Distribution & Payment for Prescription Drugs





Distribution & Payment for Prescription Drugs

A Simplified Representation

WAC



Total Paid Amount

* WAC does not represent actual transaction prices and does not include discounts, rebates, or other reductions in price.



Wholesale Acquisition Cost (WAC)

WAC – is a list price set by the manufacturer that does not include discounts or rebates.

The term "wholesale acquisition cost" means, with respect to a drug or biological, the manufacturer's list price for the drug or biological to wholesalers or direct purchasers in the United States, not including prompt pay or other discounts, rebates or reductions in price, for the most recent month for which the information is available, as reported in wholesale price guides or other publications of drug or biological pricing data.

Source: 42 USC § 1395w-3a(c) (6) (/uscode/text/42/1395w-3a#c_6)






Term	Definition		
Federal upper	A price ceiling used by the Centers for Medicare and Medicaid Services		
limit (FUL)	(CMS) to control prices for certain medications paid to pharmacies		
Maximum allowable cost (MAC)	A price ceiling, similar to the FUL, established at the state level		
Usual and customary price (U&C)	The average cash price paid at a retail pharmacy		
Average wholesale	An estimate of the price retail pharmacies pay for drugs from		
price (AWP)	their wholesale distributor. This price is calculated and published		
	by companies such as Medi-Span and First Databank		
Wholesale acquisition cost (WAC)	An estimate of the manufacturer's list price for a drug to		
	wholesalers or other direct purchasers, not including discounts		
	or rebates. This price is defined by federal law		
Average manufacturer price (AMP)	The price a manufacturer charges wholesalers or pharmacies that		
	purchase directly from the manufacturer after discounts. This price		
	is defined by federal law		
Average sales	A calculation of the weighted average of manufacturer's sales price		
price (ASP)	for a drug for all purchasers, net of price adjustments. This price is		
	defined by federal law		
Estimated acquisition	An estimate of the price generally paid by providers for a drug.		
cost (EAC)	Formula specific for each state as defined by the state Medicaid agency		
Average Actual	An estimate of retail pharmacy acquisition costs for drugs through		
cost (AAC)	a review of actual pharmacy invoices		
Dispensing fee	The amount reimbursed to the pharmacy to cover the charge for		
	professional services and overhead costs		
National Drug	An II-digit code used by Medicaid to identify a drug based on its		
Code (NDC)	manufacturer, strength, and package size		
Source: References 3-5, 7, 14.			

Table 1. Common Terms and Acronyms Used in Drug Pricing

Source: Joey Mattingly, Understanding Drug Pricing, US Pharm. 2012;37 (6) (Generic Drug Review suppl):pp. 40-45.



Medicaid Fee-For-Service Drug Payment & Rebate Flow



Source: MACPAC (Medicaid and CHIP Payment and Access Commission), Medicaid Payment for Outpatient Prescription Drugs, Issue Brief, May 2018.








University of Minnesota



Drug Product & Drug Payment Flow for Outpatient Prescriptions




Source: Data from: Fein, Adam J., The 2017 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers, Drug Channels Institute, 2020.






Channels of Distribution for Prescription Drugs




Source: Compiled by PRIME Institute, University of Minnesota from data found in DDD Annual Class of Trade Analysis (Plymouth Meeting, PA: IMS, 2006-2013) and reported in *The Chain Pharmacy Industry Profile*, 2006-2013.

Shift in Channels of Distribution & Drug Type




Sources of Payment for Prescription Drugs



Top PBMs in the Market

PBM Market Share of Prescription Claims: 2022



Source: Data from The 2023 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers, Drug Channels Institute, May 23, 2023, Exhibit 98.





PBM Functions

A Partial List of Functions

Benefit Management

- Process Rx Claims
- Benefit Design & Coverage

Clinical Programs

- Develop & Maintain Drug Formulary
- Encourage Generic & Therapeutic Substitution
- Perform Utilization Management & Review (*e.g.*, Prior authorization, Step Therapy, Quantity Limits)
- Encourage Patient Compliance

Distribution Programs

- Operate a Network of Retail Pharmacies
- Operate (and Own) a Mail Order Pharmacy
- Operate (and Own) a Specialty Pharmacy

Financial Programs

- Negotiate Rebates
- MAC Prices for Generics
- Manage Copay Accumulators & Cost-Share Maximizers
- Administer Coupons & Discount Card Programs

Source: Understanding the Evolving Business Models and Revenue of Pharmacy Benefit Managers, PBM Accountability Project, 2021, www.pbmaccountability.org



Vertical Integration in Health Care

Vertical Business Relationships Among Insurers, PBMs, Specialty Pharmacies, and Providers, 2023



- Vertical systems provide opportunity for efficiency and integration.
 - Vertical systems can channel patients from Insurer to PBM to Pharmacy, or other providers.
- Vertical systems have potential conflicts of interest & may pay their own providers more than they pay others.

Source: Adam J Fein, Mapping the Vertical Integration of Insurers, PBMs, Specialty Pharmacies, and Providers: A May 2023, Update, Drug Channels, Drug Channels Institute; see also, Jose R Guardado, Competition in Commercial PBM Markets and Vertical Integration of Health Insurers with PBMs: 2023 Update, Policy Research Perspectives, American Medical Association, September 2023.

٠



Why Are There Rebates?

Rebates:

A means to alter the pattern of drug prescribing and use based on payments from the manufacturer to achieve objectives that otherwise would not have happened.

Manufacturer objectives for rebates:

- Increased volume of sales
- Increased market share of a defined set of products
- Improved outcomes by a defined measure
- Or, other factors defined by contract

PBM objectives for rebates:

- Place Brand in a favorable position
- Create a revenue stream from rebates
- Create a revenue stream from rebate administration





Private Market Rebates: 2023

Which product would you put on the formulary based on economics?

Drug Product A	or	Drug Product B
• 50% Rebate Off of V	VAC	0% Rebate Off of WAC
 AWP = \$11.01 / Cap WAC = \$ 9.18 / Cap (Nexium, 40 mg, DR cap, Astra 	aZeneca)	AWP = \$ 8.52 / Cap WAC = \$ 0.51 / Cap (esomeprazole mag., 40 mg, DR cap, Teva)
\$4.59/Cap Rebate If the PBM Keeps the Rel	oate, Whic	\$ 0.00/Cap Rebate h Product Would the PBM Prefer?
 Net Cost = \$ 9.18 - 5 = \$ 4.59 If Plan Sponsor Wants to Pay Log 		Net Cost = \$0.51 – 0% = \$ 0.51 ost, Which Product Would the Plan Prefer?

More Rebate Does Not Always Mean Lowest Net Price



Rebates By Any Other Name...

What are the various forms of rebates?

- Rebate Administration Fees are Rebates
- Price Protection Payments are Rebates
- Data Management Fees are Rebates
- Research Access Fees are Rebates
- Formulary Placement Fees are Rebates
- Other Types of Payments may be Rebates

A Larger Rebate Does Not Necessarily Mean You Get a Lower Net Cost

Rebates by Any Other Name are Still KICKBACKS



Private Market Rebates: 2023

What are rebate levels in the private market?

- 8.824 NDCs Covered & Used in 2023
- 401 NDCs (4.5%) Have Rebate in 2023
- Rebates are 30.5% of Total Paid for All NDCS
- Rebates are 43.5% of Total Paid for NDCs w/Rebate
- NDCs with Rebates are 70.2% of Total Paid
- **Rebates for Single Source Brands:** ۲
- **Rebates for Co-Licensed Brands:**
- **Rebates for Originator Off-Patent Brands:** 74.7%
- Rebates for Generics:
- **Rebates by Formulary Tier 1:** 53.4% **Rebates by Formulary Tier 2:** 43.6% 27.7%
- **Rebates by Formulary Tier 3:**

More Rebate Does Not Always Mean Lowest Net Price




42.5%

58.5%


0.0%

Impact of Rebates on Drug Prices






Impact of Rebates on Drug Prices






Impact of Rebates on Drug Prices



PRIME Institute University of Minnesota



Generic MAC Amount Paid/Unit to PBM to Pharmacy & by Client to PBM



Market Observations

Sometimes a PBM has a different MAC list to pay pharmacies & to bill its clients.

PBMs charge a SPREAD on some prescriptions: the client pays more to the PBM than the PBM paid the pharmacy.

PBMs also may use different MAC lists for different clients.

Who benefits from the MAC spread on generic prescriptions?

Who benefits when the pharmacy MAC is reduced?


Is Mail order paid the same MAC as other retail pharmacies? ---Not always, sometimes it is higher

Who owns the mail order? ----the PBM

This Market is Broken.



Amount Paid/Unit for Generic Prescription Drug by Pharmacy Type & Network Status



Market Observations

Is the Preferred Network ---Less Expensive? or ---More Expensive?

Why Are Prices Higher for Preferred Network Pharmacies?

Who owns the Preferred Network Pharmacies? ----the PBM owns most of them

This Market is Broken.



Factors Influencing Drug Expenditures

Total Drug Expenditures =

[Population x Intensity x Efficiency] + Admin. Costs - Rebates

(& Other Fees)

of People Age, Gender Region Ethnicity Units/Person/Yr (Rx/Person/Yr) Dose Intensity Indication Diagnosis Severity


Cost/UnitBenefit Mgmt.(Cost/Rx)DURDrug of ChoiceFormulary Mgmt.Brand vs. GenericPrior AuthStep Therapy

Rebate Negot. Rebate Admin. Rebate \$ (& %) DIR Fees Net Drug Cost



PRIME Institute University of Minnesota

Components of Prescription Price







Payer

Who Is the Payer?

- **Insurer** (Not Really Payer → Processes Transactions)
- **PBM** (Not Really Payer → Processes Transactions)

So Who Really Is the Payer? Person Who Pays Cash → Individual Employer → Employee → Individual Government → Taxpayer → Individual (Medicare, Medicaid, DOD, VA, IHS, Other)





Health Care is <u>Not</u> a Free Benefit*

We all pay for health care, directly or indirectly.

- Out-of-Pocket Cost (copays, co-insurance, deductible)
- Insurance Premiums (employer, self-insured)
- Employer Paid Insurance v. Lower Wages
- Tax Supported Govt. Programs

(Medicare, Medicaid, VA, IHS, NIH, other)

- Insurance does not reduce the cost of health care, it merely redistributes it.
- Insurance premiums are also an out-of-pocket cost.





Cost-Sharing Methods


Premium

- \$700 per month
- Deductible
 - \$200 per occurrence / \$500 per year (or more)

Coinsurance

- 10% to 50% of expenditures incurred
- Copayment
 - \$10 to \$150 per event or use
- Annual Cap
 - **\$1,000 per year**
- Lifetime Cap
 - \$1,000,000 health expenditures






HRI analysis of sources: 2010 US National Health Expenditures and IMS Institute for Healthcare Informatics

Source: *Unleashing value:* The changing payment landscape for the US pharmaceutical industry, *Health Research Institute, May 2012, pwc*











Is Affordability An Issue?

What evidence do we have of affordability issues?

Poll of Americans found that:

• 25% say difficult to afford cost of medications

Affordability of medications is a problem for:

- 33% of those who take 4 or more prescription drugs
- 31% of those who are age 18-49
- 58% with >\$100 monthly drug cost
- 49% of persons with fair or poor health
- 40% of Hispanics, 30% of Blacks, & 24% of Whites
- 33% with < \$40,000 annual income have not filled Rx or skipped a dose

Actions taken due to cost of prescription drugs:

- 23% did not fill prescription, cut pills in half, or skipped doses due to cost
- 10% purchased or attempted to get drugs from outside the U.S.
- 8% traded, accepted meds from another person, or used leftover meds

Source: Alex Montero, Audrey Kearney, Liz Hamel. Mollyann Brodie, Americans' Challenges with Health Care Costs, Kaiser Family Foundation, Published: Jul 14, 2022, https://www.kff.org/health-costs/issue-brief/americans-challenges-with-health-care-costs/#



How Much is Your Life Worth? How Much Do You Have in the Bank? That Is How **Economic Markets Work!** Is That How Access to **Health Care Should Work ? Our Expectations & Choices May Not Be Ethical or Sustainable!**



The Pharmaceutical Market is Very Dynamic and Constantly Changing

It is important to be explicit about the assumptions we make and to monitor for exceptions and changes in expected relationships.

PRIME Institute University of Minnesota

